BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31606550)

  • 1. Modulation of FLT3 signal transduction through cytoplasmic cysteine residues indicates the potential for redox regulation.
    Böhmer A; Barz S; Schwab K; Kolbe U; Gabel A; Kirkpatrick J; Ohlenschläger O; Görlach M; Böhmer FD
    Redox Biol; 2020 Jan; 28():101325. PubMed ID: 31606550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.
    Jayavelu AK; Müller JP; Bauer R; Böhmer SA; Lässig J; Cerny-Reiterer S; Sperr WR; Valent P; Maurer B; Moriggl R; Schröder K; Shah AM; Fischer M; Scholl S; Barth J; Oellerich T; Berg T; Serve H; Frey S; Fischer T; Heidel FH; Böhmer FD
    Leukemia; 2016 Feb; 30(2):473-83. PubMed ID: 26308771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation.
    Tsitsipatis D; Jayavelu AK; Müller JP; Bauer R; Schmidt-Arras D; Mahboobi S; Schnöder TM; Heidel F; Böhmer FD
    Oncotarget; 2017 Apr; 8(16):26613-26624. PubMed ID: 28460451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD.
    Kazi JU; Chougule RA; Li T; Su X; Moharram SA; Rupar K; Marhäll A; Gazi M; Sun J; Zhao H; Rönnstrand L
    Cell Mol Life Sci; 2017 Jul; 74(14):2679-2688. PubMed ID: 28271164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.
    Poitras JL; Heiser D; Li L; Nguyen B; Nagai K; Duffield AS; Gamper C; Small D
    Oncotarget; 2016 Oct; 7(43):69124-69135. PubMed ID: 27636998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOX-driven ROS formation in cell transformation of FLT3-ITD-positive AML.
    Jayavelu AK; Moloney JN; Böhmer FD; Cotter TG
    Exp Hematol; 2016 Dec; 44(12):1113-1122. PubMed ID: 27666490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation.
    Li Y; Yang W; Patel RM; Casey EB; Denby E; Mendoza-Castrejon J; Rodriguez-Lopez P; Magee JA
    Blood; 2023 Mar; 141(12):1442-1456. PubMed ID: 36395068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficiency of core fucosylation activates cellular signaling dependent on FLT3 expression in a Ba/F3 cell system.
    Duan C; Fukuda T; Isaji T; Qi F; Yang J; Wang Y; Takahashi S; Gu J
    FASEB J; 2020 Feb; 34(2):3239-3252. PubMed ID: 31908039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
    Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
    J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A noncanonical Flt3ITD/NF-κB signaling pathway represses DAPK1 in acute myeloid leukemia.
    Shanmugam R; Gade P; Wilson-Weekes A; Sayar H; Suvannasankha A; Goswami C; Li L; Gupta S; Cardoso AA; Baghdadi TA; Sargent KJ; Cripe LD; Kalvakolanu DV; Boswell HS
    Clin Cancer Res; 2012 Jan; 18(2):360-369. PubMed ID: 22096027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Vulnerabilities in
    Uras IZ; Maurer B; Nebenfuehr S; Zojer M; Valent P; Sexl V
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia.
    Zhang Y; Askenazi M; Jiang J; Luckey CJ; Griffin JD; Marto JA
    Mol Cell Proteomics; 2010 May; 9(5):780-90. PubMed ID: 20019052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
    Chougule RA; Kazi JU; Rönnstrand L
    Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B; Zhao Y; Wang X; Gong P; Ge W
    Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
    Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
    Kiyoi H; Kawashima N; Ishikawa Y
    Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
    Nguyen B; Williams AB; Young DJ; Ma H; Li L; Levis M; Brown P; Small D
    Oncotarget; 2017 Feb; 8(7):10931-10944. PubMed ID: 28077790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
    Köthe S; Müller JP; Böhmer SA; Tschongov T; Fricke M; Koch S; Thiede C; Requardt RP; Rubio I; Böhmer FD
    J Cell Sci; 2013 Oct; 126(Pt 20):4746-55. PubMed ID: 23943874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.